Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

By G. Gao, Mauricio Alvira, Lili Wang, R. Calcedo, J. Johnston, James M. Wilson. Proceedings of the National Academy of Sciences of the United States of America, 2002

1,527 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/b4f2776ab380327a1cc7d3e3d35b944e495a7961

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Molecular Biology

Citations in the corpus

Worldwide Epidemiology of Neutralizing Antibodies to Adeno-Associated Viruses (2009, methodology): “LacZ vectors used in this study were made by the Vector Core of the University of Pennsylvania (Philadelphia, PA), as described elsewhere [17].”
Adeno-associated virus serotypes: vector toolkit for human gene therapy. (2006, background): “For instance, AAV8 displays a propensity for liver transduction, while AAV7 transduces muscle with efficiency similar to that of AAV1, the most efficient serotype for muscle transduction identified so far [16].”
Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart (2005, background): “Recently, a number of new AAV serotype vectors, including AAV7 and AAV8, have become availabl”
Progress and problems with the use of viral vectors for gene therapy (2003, background): “AAV vector genomes flanked by AAV2 inverted terminal repeats (ITRs) have also been successfully cross-packaged in the capsids of alternative serotypes, creating a portfolio of pseudotypes with different specificitie”
Adeno-associated virus as a delivery vector for gene therapy of human diseases (2024, background): “12,13,25 Human seroprevalence studies have revealed that a signi ﬁ cant proportion of populations possess neutralizing antibodies (NAbs) against multiple AAV serotypes.”
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues (2004, methodology): “from human and nonhuman primate tissues as described previously (10).”
Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. (2008, neutral): “5 μg of pTRCMVLuc and pXR (1-9) and 15 μg of pXX680.”
Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. (2006, background): “Many in vivo studies have demonstrated that rAAV vectors packaged in alternative AAV serotype capsids exhibit serotype-specific tissue- or cell-type tropism and/ or increased transduction efficiency [1,2,9].”
Immune responses to AAV vectors: overcoming barriers to successful gene therapy. (2013, neutral): “99%, but studies with naturally occurring serotypes 56 and purpose-engineered capsids 57-59 have shown that even small differences in capsid sequence may affect tissue tropism of a vector and can be exploited to improve therapeutic outcomes.”
Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors (2010, neutral): “1 for AAV2 (Li et al. , 1997), pLT-RC02 for AAV1 (Riviere et al. , 2006), pLT-RC03 for AAV5 (Riviere et al. , 2006), pLTRCO6 for AAV6 (Riviere et al. , 2006), p5e18-VD2-8 for AAV8 (Gao et al. , 2002), and pAAV-2 = 9 for AAV9 (Gao et al. , 2004); and the relevant pAAV2 vector plasmid.”